Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OPKO Health Inc submits IND for Rayaldee as Adjunctive Cancer Therapy


Thursday, 7 Aug 2014 03:35pm EDT 

OPKO Health Inc:Submits Investigational New Drug (IND) Application to the United States (U.S.) Food and Drug Administration (FDA).Under which Rayaldee will begin clinical evaluation as adjunctive therapy for prevention of skeletal-related events (SREs) in patients with bone metastases undergoing anti-resorptive therapy. 

Company Quote

10.82
-0.6 -5.25%
4:03pm EDT